Enclomiphene
- Status
- Phase 3, , not approved for human use
- Evidence
Not graded on a research bench yet
Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility.
Reviewed
01Overview
What Enclomiphene is
Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a mixture of two geometric isomers, trans (enclomiphene) and cis (zuclomiphene), with 30% to 50% of the cis isomer, enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile.
Read the full overviewShow less
In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Negative feedback from circulating estradiol normally throttles gonadotropin-releasing hormone (GnRH) pulse generation; when enclomiphene occupies these receptors, the hypothalamus is "blinded" to estrogen, GnRH pulse frequency increases, the pituitary ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and the testes respond by increasing endogenous testosterone production and spermatogenesis. The net clinical effect, in men with a functional HPG axis that is simply being under-driven (secondary hypogonadism), is a restoration of serum total testosterone into the mid-normal range — often 500-700 ng/dL from baselines below 300 ng/dL — while preserving or improving sperm count, motility, and morphology. This stands in sharp contrast to exogenous testosterone replacement therapy (TRT), which suppresses LH/FSH, shuts down intratesticular testosterone production, and typically drives sperm counts toward azoospermia within 3-6 months of use ([Anawalt, 2020]).
Enclomiphene sits in an unusual regulatory limbo. Repros Therapeutics ran two successful Phase 3 trials (ZA-301 and ZA-302) in overweight men with secondary hypogonadism, demonstrating that once-daily 12.5 mg or 25 mg enclomiphene restored morning total testosterone while maintaining or increasing sperm concentration relative to both placebo and topical testosterone gel ([Kim et al., 2016]). Despite these results, the FDA declined to approve Androxal in 2015, citing concerns about the clinical meaningfulness of the primary endpoints and the absence of long-term cardiovascular outcomes data — concerns that parallel the broader regulatory pushback against all low-T treatment paradigms during the 2013-2016 era. Repros subsequently went bankrupt, and the molecule fell into a commercial gray zone: not FDA-approved, but sold widely through US telehealth clinics and compounding pharmacies under state physician supervision as an "off-label" or "investigational" testosterone tuning tool, particularly for men who want to avoid the fertility penalty of TRT.
For bodybuilders, biohackers, and men pursuing testosterone tuning, enclomiphene has become a central pillar of the "fertility-preserving" and "post-cycle therapy" toolkits. It is used as (1) a monotherapy for men with secondary hypogonadism who want natural production rather than exogenous testosterone; (2) a post-cycle therapy (PCT) agent after anabolic steroid cycles to restart the HPG axis; (3) an adjunct or alternative to hCG for men on TRT who want to preserve testicular volume and fertility; and (4) a mild endogenous testosterone booster in men with borderline hypogonadism or age-related T decline. Its oral dosing, lack of injection requirement, favorable side effect profile relative to clomiphene itself, and fertility-preserving mechanism make it one of the more popular prescription-gray-market molecules in the men's health tuning space.
This entry covers the full pharmacology, clinical evidence base, protocol considerations, and safety profile of enclomiphene citrate. It is intended for educational and research reference only — enclomiphene is a prescription drug in most jurisdictions, is NOT FDA-approved for any indication, and the decision to use it should involve a qualified physician who can order appropriate baseline and follow-up labs (total testosterone, free testosterone, estradiol, LH, FSH, SHBG, CBC, CMP, lipid panel, and semen analysis when fertility is a concern). Cross-reference this page with HCG, Gonadorelin, and Kisspeptin-10 for a complete picture of HPG axis modulation strategies.
How it works
Primary Mechanism: Central Estrogen Receptor Antagonism
Enclomiphene is a non-steroidal triphenylethylene with a molecular structure closely related to tamoxifen. Pharmacologically, it behaves as a mixed agonist/antagonist at estrogen receptors — a classical SERM profile — but with tissue-specific effects that differ markedly from tamoxifen, raloxifene, and other SERMs used in oncology and osteoporosis.
Read the full mechanismShow less
At the hypothalamus and anterior pituitary, enclomiphene is a pure antagonist of estrogen receptor alpha (ERα). Under physiological conditions, circulating estradiol (E2) — most of which is produced in men via peripheral aromatization of testosterone in adipose tissue, liver, and skin — binds hypothalamic ERα and provides the major negative feedback signal that throttles GnRH pulse generation. This feedback loop is the biological governor on the HPG axis: as testosterone rises, aromatization generates estradiol, estradiol suppresses GnRH, and LH/FSH output falls, completing the circuit.
When enclomiphene occupies hypothalamic ERα, estradiol can no longer exert this suppressive feedback. The hypothalamus perceives the estrogen signal as absent and responds by:
- Increasing GnRH pulse frequency: Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) are derepressed, leading to more frequent GnRH bursts ([Dwyer et al., 2015]).
- Amplifying pituitary gonadotroph response: The pituitary becomes more sensitive to GnRH stimulation, producing larger LH and FSH pulses per GnRH input.
- Driving downstream testicular steroidogenesis: LH stimulates Leydig cells to synthesize testosterone from cholesterol via the classical steroidogenic pathway (StAR → P450scc → 3β-HSD → CYP17 → 17β-HSD). FSH supports Sertoli cell function and spermatogenesis.
The net effect is an upward shift in the entire HPG axis set point — higher LH, higher FSH, and higher endogenous testosterone — without exogenous hormone administration. In clinical studies, typical LH increases range from 2-4x baseline, testosterone rises 50-100% from hypogonadal baseline, and the effects are maintained with chronic dosing because enclomiphene does not accumulate or cause tachyphylaxis ([Kaminetsky et al., 2013]).
The Enclomiphene vs. Zuclomiphene Distinction
Clomiphene citrate as prescribed for female ovulation induction is a mixture of two geometric isomers: enclomiphene (the trans, or E, isomer) and zuclomiphene (the cis, or Z, isomer), with 30% to 50% of the cis isomer according to the US prescribing information. These two molecules differ only in the geometric orientation around a single double bond, but their pharmacology is dramatically different:
- Enclomiphene is a short-acting ERα antagonist with a half-life of approximately 10 hours and complete clearance within 1-2 weeks of discontinuation. It does NOT accumulate with chronic dosing.
- Zuclomiphene is a long-acting weak ERα agonist with a half-life of 30+ days and measurable tissue concentrations for months after stopping chronic therapy. It DOES accumulate.
This distinction matters enormously for men. When men take clomiphene long-term (the common "clomid TRT" approach), zuclomiphene gradually accumulates and begins to produce estrogen-agonist effects: visual disturbances (shimmering, floaters, rarely permanent retinal changes), mood destabilization (depression, anxiety, emotional lability), libido suppression paradoxically overriding the testosterone boost, and potentially long-term safety concerns from chronic ERα agonism in a male. Many of the complaints men have about "clomid" — the mood crashes, the vision issues, the libido problems — are attributable to zuclomiphene rather than to the antagonist component.
Purifying enclomiphene removes zuclomiphene entirely. The result is a cleaner molecule that delivers the HPG axis stimulation without the off-target agonist burden. In head-to-head comparisons and clinical trials, enclomiphene produces substantially fewer mood, visual, and libido side effects than equipotent doses of clomiphene ([Wiehle et al., 2013]). This is the central pharmacological argument for using enclomiphene rather than clomiphene for extended HPG axis support.
Fertility Preservation Pharmacology
The clinical feature that sets enclomiphene apart from exogenous testosterone is its effect on spermatogenesis. Exogenous testosterone (whether injectable, topical, or oral) suppresses LH and FSH via direct pituitary negative feedback after peripheral conversion to estradiol and via direct androgen receptor feedback in the hypothalamus. This suppression drops intratesticular testosterone concentrations from their normal range of 500-1,000 ng/mL down to serum levels (5-10 ng/mL) — a 50-100x decrease. Since spermatogenesis requires extraordinarily high local testosterone concentrations (20-100x serum levels) to proceed through meiosis, the result is progressive oligospermia and, in most men, frank azoospermia within 3-6 months of consistent TRT use.
Enclomiphene has the opposite effect. By stimulating rather than suppressing the HPG axis, it drives LH to support intratesticular testosterone production AND drives FSH to support Sertoli cell function and spermatogenesis directly. In men with baseline sub-fertility from secondary hypogonadism, enclomiphene typically improves sperm concentration, motility, and total motile count over 3-6 months of therapy ([Shabsigh et al., 2005] on clomiphene, with analogous data for enclomiphene). For men who want both symptomatic relief from low testosterone AND preservation of reproductive potential, this is a substantial advantage over TRT.
Hepatic Metabolism and Pharmacokinetics
Enclomiphene is orally bioavailable with peak plasma concentrations reached 4-8 hours after dosing. It undergoes extensive first-pass hepatic metabolism primarily via CYP2D6 and CYP3A4, with the main metabolite 4-hydroxy-enclomiphene retaining some antiestrogenic activity. Terminal elimination half-life is approximately 10 hours, which is why once-daily dosing is adequate for stable LH/FSH elevation. Excretion is primarily biliary/fecal, with minor urinary elimination.
Because of CYP2D6 involvement, men who are CYP2D6 poor metabolizers (~7% of Caucasians, ~2% of East Asians) may experience higher plasma concentrations and more pronounced effects at standard doses. CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) may also elevate enclomiphene levels modestly, though clinically significant interactions are uncommon. CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) may reduce enclomiphene plasma levels and blunt response.
Off-Target Receptor Activity
Relative to tamoxifen and other SERMs, enclomiphene has minimal off-target activity at estrogen receptor beta (ERβ), androgen receptor, progesterone receptor, or glucocorticoid receptor. This relatively clean receptor profile contributes to its favorable tolerability in men, as most SERM-related side effects (hot flashes with tamoxifen, endometrial effects, bone density changes) arise from tissue-specific agonism at ERα in organs outside the HPG axis. Enclomiphene appears to be a near-pure HPG-axis modulator with minimal extra-axis activity at therapeutic doses.
Benefits listed
- Increased endogenous testosterone production
- HPTA axis restoration after suppression
- Maintained fertility during TRT
- Improved LH and FSH levels
Show 1 moreShow less
- Fewer estrogenic side effects than clomiphene
02Research
Free with emailWhat the research shows
No research bench grades Enclomiphene yet. Benches compare compounds people pair, with the evidence for each.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Enclomiphene side effects and interactions
Side effects
Not in our record
Who should not use it
Contraindications
Absolute Contraindications
Enclomiphene must NOT be used in the following conditions:
- Known hypersensitivity to enclomiphene, clomiphene, or other triphenylethylene SERMs — cross-reactivity possible
- Pregnancy — enclomiphene is not intended for use in women, and would be strongly contraindicated if pregnancy were somehow involved; category X analog equivalent
- Current or history of thromboembolic disease — deep vein thrombosis, pulmonary embolism, stroke. SERM class carries theoretical and some empirical VTE risk.
- Known thrombophilia — Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin deficiency. Elevated baseline VTE risk may be further increased by SERM therapy.
- Active or recent myocardial infarction — especially within 6 months
- Uncontrolled heart failure — NYHA Class III-IV or decompensated disease
- Severe hepatic impairment — Child-Pugh Class C; metabolism will be impaired and hepatotoxicity risk elevated
- Untreated pituitary adenoma or mass lesion — enclomiphene assumes intact pituitary function; macroadenomas should be identified and addressed first
- Primary (testicular) hypogonadism with maximally elevated LH — enclomiphene cannot work when the testes themselves are the limiting factor and LH is already maximally stimulated
- Men seeking contraception or attempting NOT to preserve fertility — enclomiphene enhances rather than suppresses fertility; if fertility preservation is specifically undesired (e.g., due to genetic disease concerns), TRT may be preferable
Read all the contraindications and cautionsShow less
Relative Contraindications / Use with Extreme Caution
- Moderate hepatic impairment (Child-Pugh Class A-B): Reduce dose, monitor LFTs more frequently
- Moderate cardiovascular disease (stable angina, prior MI >6 months ago, controlled heart failure): Case-by-case assessment, stricter monitoring
- Prior VTE risk factors (prolonged immobilization planned, active malignancy, advanced age, combined HRT use): Assess individual risk
- History of mood disorders: Screen carefully, monitor closely, consider dose adjustments; some men have significant mood effects even on enclomiphene
- Visual disorders or prior issues with clomiphene: Watch carefully for visual symptoms; may still be usable at lower doses
- Erythrocytosis or pre-existing elevated hematocrit: Higher baseline risk of supra-physiologic hematocrit with T elevation; frequent monitoring
- Prostate disease: Baseline and follow-up PSA; BPH may worsen with androgen elevation; known prostate cancer is controversial but generally contraindicated
- Polycystic ovarian syndrome or hormonal disorders in partners: Not a contraindication for the male user, but worth noting for fertility planning
- Concurrent CYP2D6 inhibitors or inducers: Monitor for over/under-response; titrate cautiously
Specific Drug Interactions
- SSRIs/SNRIs (fluoxetine, paroxetine, duloxetine): CYP2D6 inhibition may elevate enclomiphene; also potential additive mood effects
- Bupropion: CYP2D6 inhibition; additive mood monitoring
- Warfarin and anticoagulants: SERM class may increase INR and bleeding risk; monitor more frequently; generally not combined unless necessary
- Tamoxifen: Combining two SERMs is rarely appropriate; if clinically indicated, close specialist supervision required
- Raloxifene: Similar overlap concerns; use one SERM at a time
- Letrozole, anastrozole, exemestane (AIs): Combination is rational for estradiol management but requires careful dose titration to avoid E2 crash
- Testosterone: Concurrent use is debated; clinicians using this combination should document rationale
- hCG: Combination is useful and well-tolerated for HPG axis optimization
- GnRH analogs (leuprolide, goserelin): Pharmacologically opposing; don't combine
- Hormonal contraceptives or cyclic progestins: Not applicable to male users; female partners using these have no interaction concern
- Thyroid medications: No direct interaction; ensure thyroid status optimized independently
- Kratom, opioids: Chronic opioid use suppresses HPG axis directly and may mask enclomiphene benefit; consider opioid status in evaluation
Lifestyle and Supplement Interactions
- Alcohol: Heavy alcohol use impairs HPG axis independently, causes hepatic stress relevant to drug metabolism, may negate clinical benefit. Moderate (<7 drinks/week) generally fine.
- Grapefruit juice: CYP3A4 inhibition; may elevate enclomiphene levels. Avoid excessive intake.
- St. John's wort: Strong CYP3A4 inducer; may reduce enclomiphene levels. Avoid concurrent use.
- Anabolic steroids or SARMs: Masks HPG axis status and defeats purpose of enclomiphene therapy. Disclose all use to prescribing clinician.
- Soy isoflavones (high-dose supplements): Weak ERα agonists; theoretical interaction. Dietary soy is not a concern.
- DHEA, pregnenolone, androstenedione: Hormonal precursors; may confound lab interpretation and HPG axis assessment. Discuss with clinician.
Pre-Treatment Workup Requirements
Before initiating enclomiphene, ensure:
- Two separate morning fasting testosterone measurements confirming low T
- LH and FSH confirming secondary (or mixed) hypogonadism pattern
- Prolactin within normal range, OR worked up and treated
- Thyroid function optimized
- Age-appropriate prostate screening (PSA if >40)
- Baseline hematocrit, lipids, LFTs
- Assessment for sleep apnea (treats secondary hypogonadism without drugs if present)
- Medication review for confounding agents (chronic opioids, cannabis in some users, certain psychiatric medications)
- Weight and lifestyle assessment — weight loss alone may resolve secondary hypogonadism in obese men
- Pituitary evaluation if clinical concern (visual field issues, other pituitary hormone abnormalities, structural symptoms)
Monitoring for Adverse Response
- Any visual symptom: discontinue, ophthalmology referral
- Mood destabilization beyond mild: reassess continuation
- Signs of VTE (leg pain/swelling, chest pain, dyspnea): immediate emergency evaluation
- Jaundice, dark urine, severe abdominal pain: immediate LFT check
- Severe headache unresponsive to conservative measures: discontinue, neurology evaluation
- Chest pain, dyspnea, leg edema: cardiology evaluation
Pregnancy and Lactation
Enclomiphene is not indicated in women or during pregnancy. Male use does not affect female partners directly, but if fertility success results in pregnancy, no continued exposure to enclomiphene for the pregnant partner occurs or is relevant.
Pediatric Use
Not indicated in pediatric populations. Adolescent hypogonadism requires pediatric endocrinology specialist evaluation.
Interactions
3 pairings in our record: 3 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
Gonadorelin
SynergisticGnRH pulsing + SERM for complete hormonal axis support
Kisspeptin-10
CompatibleBoth support the HPG axis through different mechanisms
Semaglutide
CompatibleNo known interaction — can be used concurrently for weight and hormonal optimization
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailEnclomiphene dosage and protocols
- Dose range
- 6,250–25,000 mcg (6.25–25 mg) oral daily
- Dosing
- Once daily oral
- Common vials
- 12.5mg capsules, 25mg capsules
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
- Stacking notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Enclomiphene prices
3 listings from 2 vendors, opening in the Featured order.
- Pack prices
- $59.99 to $99.99
- Lowest per mg
- $0.213/mg
- Vendors
- 2
- Listings
- 3 (capsule, liquid)
Prices as the vendors list them, last recorded 27 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
Liquid Enclomiphene 12.5 mg/mL liquid, 30 mL (12.5 mg/mL) In stock | $0.213/mg $79.99 Lowest per mg | Buy Liquid Enclomiphene 12.5 mg/mL at Disguised Alpha | |
Enclomiphene Citrate Capsules capsule, capsules In stock | $99.99 No mg count | Buy Enclomiphene Citrate Capsules at Disguised Alpha | |
Enclomiphene Capsules 60ct capsule, 60 capsules In stock | $59.99 No mg count | Buy Enclomiphene Capsules 60ct at Half Nattys |
Vendors selling Enclomiphene(2: trust score, certificates, payment, shipping)
- Half Nattys1 listing, from $59.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- Disguised Alpha2 listings, from $79.99
Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(3 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C26H28ClNO
- Molecular mass
- 405.96 g/mol
- CAS number
- 15690-57-0
- IUPAC name
- (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-ethanamine
08Questions
Frequently asked questions
How is enclomiphene different from clomiphene (Clomid)?
Clomiphene citrate (Clomid) is a mixture of two geometric isomers: enclomiphene (the antagonist component) and zuclomiphene (a weak long-acting agonist), with 30% to 50% of the cis isomer (zuclomiphene) on the US label. Enclomiphene is the purified antagonist alone, without zuclomiphene. Because zuclomiphene has a ~30-day half-life and accumulates with chronic dosing — producing most of clomiphene's mood, visual, and libido side effects — enclomiphene offers a cleaner tolerability profile while preserving the HPG axis stimulation that raises testosterone and LH/FSH (Wiehle et al., 2013).
Is enclomiphene FDA-approved?
No. Repros Therapeutics developed enclomiphene as 'Androxal' and completed successful Phase 3 trials, but the FDA issued a Complete Response Letter in 2015 declining approval and citing concerns about the clinical meaningfulness of primary endpoints and long-term cardiovascular safety data. Repros went bankrupt in 2017. Enclomiphene remains available through US compounding pharmacies with physician prescription as an 'off-label' or investigational medication, typically in men's health clinic settings.
Does enclomiphene preserve fertility compared to testosterone replacement?
Yes, this is the central clinical advantage. Exogenous testosterone suppresses LH and FSH, which dramatically reduces intratesticular testosterone and typically produces oligospermia or azoospermia within 3-6 months. Enclomiphene does the opposite — it stimulates LH/FSH, which drives both endogenous testosterone and spermatogenesis. In the Phase 3 Repros trials, enclomiphene groups maintained or improved sperm concentration while testosterone gel reduced it by approximately 40% (Kim et al., 2016).
What dose should I start with?
12.5 mg once daily is the standard starting dose for men with secondary hypogonadism. Most men reach adequate testosterone normalization (500-800 ng/dL) at this dose within 4-6 weeks. If response is partial after 8-12 weeks, increasing to 25 mg daily is reasonable. Higher doses (50+ mg) are generally reserved for short-course PCT applications and increase side effects substantially. Always obtain baseline labs and work with a physician.
How long does it take to see results?
LH and FSH typically rise within the first week. Testosterone begins climbing noticeably by weeks 2-3 and approaches steady-state by weeks 6-8. Subjective symptom improvements (energy, libido, mood) often follow the hormonal changes with a 2-4 week lag — many men notice them by weeks 4-8. Sperm parameter changes, if present, take longer (3-6 months typically), reflecting the spermatogenesis cycle duration.
Can I take enclomiphene long-term?
Yes, enclomiphene can be continued indefinitely if tolerated and effective, based on clinical experience — there is no evidence of tachyphylaxis (loss of effect) over at least 12 months of continuous therapy, and it does not accumulate. Most long-term users settle on 12.5 mg daily or every-other-day maintenance dosing. Periodic reassessment (every 6-12 months) of ongoing need, response, and safety labs is recommended. Unlike TRT, stopping enclomiphene does not cause a dramatic hormonal crash.
What side effects are most common?
The most common side effects are headache (8-12%), nausea (6-9%), hot flashes (5-8%), mild acne (4-7%), and mild mood changes (3-6%). Visual disturbances (shimmering, floaters) occur in less than 2% but should always prompt immediate discontinuation if noticed. Most side effects are mild, occur early in therapy, and resolve with continued use or dose adjustment. Enclomiphene is substantially better tolerated than clomiphene for equivalent HPG axis effect.
Can enclomiphene be used for post-cycle therapy (PCT)?
Yes, enclomiphene is a standard PCT agent, often used at 25 mg daily for 4 weeks followed by 12.5 mg daily for 2-4 weeks. Advanced PCT protocols combine hCG (to restart testicular responsiveness) with enclomiphene plus optionally tamoxifen. PCT effectiveness depends on cycle duration, compound used, and individual HPG axis resilience. Some men recover fully; others require extended support or ultimately transition to TRT. Always baseline and follow-up labs to confirm recovery.
How does enclomiphene compare to hCG for preserving fertility on TRT?
Both can preserve testicular function and fertility alongside TRT, but mechanistically differ. hCG directly mimics LH and stimulates Leydig cells to produce intratesticular testosterone — bypassing the hypothalamus entirely. Enclomiphene blocks estrogen receptors centrally, increasing endogenous LH/FSH. On TRT, exogenous testosterone suppresses this central signaling, making enclomiphene less effective — hCG is the more conventional choice for TRT-alongside fertility preservation. Enclomiphene is best as a monotherapy (replacing TRT) rather than an adjunct.
What labs should I monitor on enclomiphene?
Baseline: total testosterone, free testosterone, estradiol (sensitive LC/MS assay), LH, FSH, SHBG, prolactin, TSH, CBC, CMP, lipid panel, PSA if age >40, semen analysis if fertility relevant. Follow-up labs at 4-6 weeks after starting or dose changes, then every 3-6 months once stable, then every 6-12 months for long-term maintenance. Target ranges: total T 500-800 ng/dL, estradiol 20-40 pg/mL, hematocrit <52%, LH typically 2-4x baseline confirming mechanistic response.
How many vendors sell Enclomiphene, and what does it cost per mg?
2 of the vendors BodyHackGuide tracks list Enclomiphene (3 listings). Among BodyHackGuide's Enclomiphene listings recorded as in stock with a milligram count, the lowest price per milligram is $0.213/mg at Disguised Alpha and the median is $0.213/mg. The Enclomiphene prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Enclomiphene listing is dated 27 October 2026.
Which vendors have third-party COAs for Enclomiphene on file at BodyHackGuide?
BodyHackGuide holds 8 third-party certificate records for Enclomiphene, from . No editor has read any of BodyHackGuide's 8 certificate records for Enclomiphene. The laboratory named on BodyHackGuide's Enclomiphene certificate records is Freedom Diagnostics Testing, and the newest test date on them is 17 September 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

